Table 1.
Characteristics of patients treated with CyberKnife for pelvic re-irradiation.
| Number (%) | Mean (range) | Comments | |
|---|---|---|---|
| Patients | 16 | ||
| Sex (M/F) | 6 (37%)/10 (63%) | ||
| Age* | 55 | (34 - 70 y.o.) | |
| Primary disease | |||
| Anal canal | 6 (38%) | ||
| Cervix | 4 (25%) | ||
| Uterus | 1 (6%) | ||
| Rectum | 4 (25%) | ||
| Bladder | 1 (6%) | ||
| Primary treatment | |||
| Surgery | 9 (56%) | ||
| Chemotherapy | 13 (81%) | 9 concomitant; 4 adjuvant | |
| Radiotherapy | 14 (87%) | ||
| Dose* | 45 Gy (20-75 Gy) | ||
| Eq D2* | |||
| Early side effects (α/β = 3 Gy) | 45 Gy (33-58 Gy) | ||
| Late side effects (α/β = 10 Gy) | 72 Gy (53-96 Gy) | ||
| Treatment of the recurrence | |||
| Surgery | 6 (38%) | ||
| Chemotherapy | 8 (50%) | ||
| Radiotherapy | 3 (19%) | ||
| Dose* | 53.7 Gy (36-66 Gy) | ||
| Eq D2* | |||
| Early side effects (α/β = 3 Gy) | 65 Gy (45-66 Gy) | ||
| Late side effects (α/β = 10 Gy) | 106 Gy (72-110 Gy) | ||
* Median value